Discover how Adobe Express's "Catch Feelings, Not Features" campaign transformed influencer marketing by focusing on ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, which Noom said will allow it to expand its behavior change programs and move beyond weight health. Tailor Made provides ...

Replace the legacy repo-local config and storage assumptions with a two-scope state model: user_state_dir for user-level CE state and per-project durable storage repo_state_dir for repo-local CE ...

Replace the single-voice document-review skill with a multi-persona review pipeline that dispatches specialized reviewer agents in parallel. Two always-on personas (coherence, feasibility) run on ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...

Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...

People who order low-cost versions of the wildly popular weight-loss drugs Wegovy and Zepbound from so-called compounding pharmacies might soon see disruptions in their medication. The U.S. Food and ...

Posts from this author will be added to your daily email digest and your homepage feed.

The US Food and Drug Administration (FDA) recently issued warning letters to more than 40 compounding pharmacies, demanding that they cease certain advertising practices for a variety of compounded ...